A long-term follow-up study on biochemical and clinical biomarkers of response to interferon beta-1b treatment in relapsing-remitting multiple sclerosis | Zendy

Anna Pietrzak | Zendy; Alicja Kalinowska-Łyszczarz | Zendy; Krystyna Osztynowicz | Zendy; A Khamidulla | Zendy; Wojciech Kozubski | Zendy; S. Michalak | Zendy

Open Access

A long-term follow-up study on biochemical and clinical biomarkers of response to interferon beta-1b treatment in relapsing-remitting multiple sclerosis

Author(s) -

Anna Pietrzak,

Alicja Kalinowska-Łyszczarz,

Krystyna Osztynowicz,

A Khamidulla,

Wojciech Kozubski,

S. Michalak

Publication year - 2020

Publication title -

advances in clinical and experimental medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.486

H-Index - 27

eISSN - 2451-2680

pISSN - 1899-5276

DOI - 10.17219/acem/121063

Subject(s) - multiple sclerosis , medicine , socs3 , interferon , biomarker , disease , oncology , immunology , biology , suppressor , cancer , biochemistry

While interferon beta-1b (IFN-β-1b) is still a commonly used disease-modifying drug in the treatment of multiple sclerosis (MS), therapeutic possibilities are expanding, and treatment failure should be identified early. Markers to predict response to IFN-β-1b, either clinical or biochemical, are therefore urgently needed. Interferon-induced proteins, including viperin, suppressor of cytokine signaling 3 (SOCS3), ubiquitin specific peptidase-18 (USP18), and myxovirus resistance protein A (MxA), are possible markers of IFN-β-1b bioavailability and treatment response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research